Christy Osgood

948 total citations
19 papers, 541 citations indexed

About

Christy Osgood is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Christy Osgood has authored 19 papers receiving a total of 541 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Christy Osgood's work include Advanced Breast Cancer Therapies (7 papers), HER2/EGFR in Cancer Research (6 papers) and Sarcoma Diagnosis and Treatment (4 papers). Christy Osgood is often cited by papers focused on Advanced Breast Cancer Therapies (7 papers), HER2/EGFR in Cancer Research (6 papers) and Sarcoma Diagnosis and Treatment (4 papers). Christy Osgood collaborates with scholars based in United States and Iraq. Christy Osgood's co-authors include Richard Pazdur, Laleh Amiri‐Kordestani, Shenghui Tang, Julia A. Beaver, Marc R. Theoret, Tiffany K. Ricks, William F. Pierce, Kirsten B. Goldberg, Patricia Keegan and Mallorie H. Fiero and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.

In The Last Decade

Christy Osgood

18 papers receiving 533 citations

Peers

Christy Osgood
Reshma Mahtani United States
Patricia Gómez Spain
Minsig Choi United States
Teresa Gelardi Italy
Caterina Fontanella Italy
Gustavo Ismael Belgium
Woo Sun Kwon South Korea
Elena Poletto Italy
Benedetta Pellegrino Italy
Jane Ruppel United States
Reshma Mahtani United States
Christy Osgood
Citations per year, relative to Christy Osgood Christy Osgood (= 1×) peers Reshma Mahtani

Countries citing papers authored by Christy Osgood

Since Specialization
Citations

This map shows the geographic impact of Christy Osgood's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christy Osgood with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christy Osgood more than expected).

Fields of papers citing papers by Christy Osgood

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christy Osgood. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christy Osgood. The network helps show where Christy Osgood may publish in the future.

Co-authorship network of co-authors of Christy Osgood

This figure shows the co-authorship network connecting the top 25 collaborators of Christy Osgood. A scholar is included among the top collaborators of Christy Osgood based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christy Osgood. Christy Osgood is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
Agrawal, Sundeep, William F. Pierce, Melanie Royce, et al.. (2024). FDA Approval Summary: Capecitabine Labeling Update under Project Renewal. Clinical Cancer Research. 30(24). 5508–5514.
3.
4.
Gao, Jennifer, Christy Osgood, Erik Bloomquist, et al.. (2023). FDA Approval Summary: Ribociclib Indicated for Male Patients with Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer. Clinical Cancer Research. 29(24). 5008–5011. 3 indexed citations
5.
Narayan, Preeti, Asma Dilawari, Christy Osgood, et al.. (2023). US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer. Journal of Clinical Oncology. 41(11). 2108–2116. 34 indexed citations
6.
Shah, Mirat, Christy Osgood, Anup Amatya, et al.. (2022). FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast Cancer. Clinical Cancer Research. 28(24). 5249–5253. 56 indexed citations
7.
Sullivan, Kathleen M., et al.. (2022). Postmarketing Colitis Cases Associated With Alpelisib Use Reported to the US Food and Drug Administration. JAMA Oncology. 8(10). 1503–1503. 4 indexed citations
8.
Royce, Melanie, Jennifer J. Lee, Christy Osgood, et al.. (2022). Abstract P5-19-02: Methodological approaches to the use of real-world data(RWD) for medical products to treat breast cancer: An FDA oncology center of excellence evaluation of RWD submissions. Cancer Research. 82(4_Supplement). P5–19. 1 indexed citations
9.
Narayan, Preeti, Christy Osgood, Harpreet Singh, et al.. (2021). FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer. Clinical Cancer Research. 27(16). 4478–4485. 118 indexed citations
10.
11.
Fashoyin‐Aje, Lola A., Christy Osgood, Joyce Cheng, et al.. (2020). FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer. Clinical Cancer Research. 27(7). 1850–1854. 114 indexed citations
12.
13.
Osgood, Christy, Flora Mulkey, Pallavi S. Mishra‐Kalyani, et al.. (2019). FDA analysis of depth of response (DpR) and survival across 10 randomized controlled trials in patients with previously untreated unresectable or metastatic melanoma (UMM) by therapy type.. Journal of Clinical Oncology. 37(15_suppl). 9508–9508. 14 indexed citations
14.
Osgood, Christy, Meredith K. Chuk, Marc R. Theoret, et al.. (2017). FDA Approval Summary: Eribulin for Patients with Unresectable or Metastatic Liposarcoma Who Have Received a Prior Anthracycline-Containing Regimen. Clinical Cancer Research. 23(21). 6384–6389. 42 indexed citations
15.
Osgood, Christy, et al.. (2017). CDK 7/9 inhibition amplifies mithramycin's suppression of Ewing sarcoma cell proliferation. The FASEB Journal. 31(S1). 1 indexed citations
16.
Osgood, Christy, Susan M. Kitchen-Goosen, Girma M. Woldemichael, et al.. (2016). Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor. Clinical Cancer Research. 22(16). 4105–4118. 57 indexed citations
17.
Osgood, Christy, Mohammed Noor Tantawy, Zachary Madaj, et al.. (2016). 18F-FLT Positron Emission Tomography (PET) is a Pharmacodynamic Marker for EWS-FLI1 Activity and Ewing Sarcoma. Scientific Reports. 6(1). 33926–33926. 10 indexed citations
18.
Osgood, Christy, Luz Elena Núñez, Javier González‐Sabín, et al.. (2015). Abstract 1612: Identification of mithramycin analogs with improved targeting of the EWS/FLI1 transcription factor. Cancer Research. 75(15_Supplement). 1612–1612. 2 indexed citations
19.
Nicholson, Maribeth R., Christy Osgood, Sari Acra, & Kathryn M. Edwards. (2015). Clostridium difficile infection in the pediatric transplant patient. Pediatric Transplantation. 19(7). 792–798. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Reshma Mahtani Breakdown of academic impact, for papers by Patricia Gómez Breakdown of academic impact, for papers by Minsig Choi Breakdown of academic impact, for papers by Teresa Gelardi Breakdown of academic impact, for papers by Caterina Fontanella Breakdown of academic impact, for papers by Gustavo Ismael Breakdown of academic impact, for papers by Woo Sun Kwon Breakdown of academic impact, for papers by Elena Poletto Breakdown of academic impact, for papers by Benedetta Pellegrino Breakdown of academic impact, for papers by Jane Ruppel
Rankless by CCL
2026